Analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to announce $1.53 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for ZIOPHARM Oncology’s earnings. The lowest sales estimate is $1.46 million and the highest is $1.60 million. ZIOPHARM Oncology posted sales of $1.60 million in the same quarter last year, which suggests a negative year over year growth rate of 4.4%. The firm is scheduled to announce its next quarterly earnings results on Monday, May 7th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full year sales of $1.53 million for the current year, with estimates ranging from $3.00 million to $6.40 million. For the next year, analysts expect that the firm will report sales of $6.40 million per share, with estimates ranging from $6.39 million to $6.40 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.59 million. During the same quarter in the prior year, the company earned ($0.11) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Thursday. HC Wainwright set a $10.00 price target on ZIOPHARM Oncology and gave the company a “buy” rating in a research report on Monday, March 5th. ValuEngine cut ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. BidaskClub cut ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Finally, Raymond James Financial reiterated a “hold” rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $7.50.
Hedge funds have recently bought and sold shares of the stock. Belpointe Asset Management LLC purchased a new stake in ZIOPHARM Oncology in the third quarter worth $746,000. Steward Partners Investment Advisory LLC purchased a new position in shares of ZIOPHARM Oncology during the 3rd quarter valued at about $145,000. Virtus Fund Advisers LLC purchased a new position in shares of ZIOPHARM Oncology during the 4th quarter valued at about $338,000. Schwab Charles Investment Management Inc. lifted its position in shares of ZIOPHARM Oncology by 6.6% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 618,589 shares of the biotechnology company’s stock valued at $3,799,000 after buying an additional 38,440 shares in the last quarter. Finally, G&S Capital LLC purchased a new position in shares of ZIOPHARM Oncology during the 4th quarter valued at about $125,000. Institutional investors own 40.15% of the company’s stock.
Shares of ZIOPHARM Oncology stock traded down $0.11 on Friday, hitting $4.34. The stock had a trading volume of 360,184 shares, compared to its average volume of 1,822,567. ZIOPHARM Oncology has a 12-month low of $3.33 and a 12-month high of $7.88. The company has a market capitalization of $633.67, a PE ratio of -8.11 and a beta of 1.42.
COPYRIGHT VIOLATION NOTICE: “ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Quarterly Sales of $1.53 Million” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/19/ziopharm-oncology-inc-ziop-expected-to-post-quarterly-sales-of-1-53-million.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.